Targeting dendritic cells to advance cross-presentation and vaccination outcomes

ElsevierVolume 68, July 2023, 101762Seminars in ImmunologyAuthor links open overlay panel, , , Abstract

Dendritic cells (DCs) are a complex network of specialised antigen-presenting cells that are critical initiators of adaptive immunity. Targeting antigen directly to DCs in situ is a vaccination strategy that selectively delivers antigen to receptors expressed by DC subtypes. This approach exploits specific DC subset functions of antigen uptake and presentation. Here, we review DC-targeted vaccination strategies that are designed to elicit effective cross-presentation for CD8+ T cell immunity. In particular, we focus on approaches that exploit receptors highly expressed by mouse and human cDCs equipped with superior cross-presentation capacity. These receptors include DEC205, Clec9A and XCR1. Targeting DC receptors Clec12A, Clec4A4 and mannose receptor is also reviewed. Outcomes of DC-targeted vaccination in mouse models through to human clinical trials is discussed. This is a promising new vaccination approach capable of directly targeting the cross-presentation pathway for prevention and treatment of tumours and infectious diseases.

AbbreviationsMHC

major histocompatibility complex

pDC

plasmacytoid dendritic cell

cDC

conventional dendritic cell

poly I:C

polyinosinic:polycytidylic acid

CTL

cytotoxic T lymphocyte

scFv

single-chain variable fragment

syk

spleen tyrosine kinase

PLGA

polylactic-co-glycolic acid

ITIM

immunoreceptor tyrosine based inhibitory motif

cGAMP

2’3- cyclic guanosine monophosphate–adenosine monophosphate

Keywords

Cross-presentation

Dendritic cells

Vaccination

Antigen presentation

View full text

© 2023 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif